Biktarvy: How Does a Three-Drug-in-One Regimen Define the Gold Standard in HIV Treatment?
In the field of HIV antiviral therapy, “simplification” and “potency” have long been the two…
News
TPIAO Approved for a New Indication: Clinical Progress of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia
(China, December 23, 2025) — Sunshine Guojian Pharmaceutical, a leading biopharmaceutical company in China, today…
Good News for Patients with Blood Cancers! World’s Third BCL-2 Inhibitor——Sonrotoclax Approved in China
On January 6, 2026, BeiGene (Suzhou) Biotech Co., Ltd. (BeiGene) ‘s independently developed innovative drug…
When Should You Take Avatrombopag Maleate (Qinganxin)—Precision Solutions for the “Platelet Crisis”
When should you take Avatrombopag Maleate (Qinganxin)? ❗ Platelets, these tiny components in the blood,…
How Ramucirumab Works: Precision Targeting of Tumour Angiogenesis
Tumour growth and metastasis are highly dependent on the formation of new blood vessels, a…
How Did Fruquintinib Elunate® Become the “Key Breakthrough” in the Treatment of Advanced Colorectal Cancer?
In advanced colorectal cancer, the exhaustion of first- and second-line standard chemotherapies and targeted therapies…
Orelabrutinib InnoCare Approval —China’s Original High-Selectivity BTK Inhibitor丨Precision Strike, New Breakthrough
On December 25, 2020, the National Medical Products Administration (NMPA) granted priority review and approval…
What Sets Saibeixin Pazopanib Tablets Apart: 5 Key Features
When it comes to domestic generic drugs, many people may instinctively associate them with stereotypes…
How Everolimus Works: Precision Targeting of Tumor Growth Pathways
For many patients with advanced renal cell carcinoma, breast cancer, or neuroendocrine tumors, targeted therapy…
Glumetinib Approval in China: A Major Breakthrough for MET-Positive Lung Cancer
On March 8, 2023, China’s National Medical Products Administration (NMPA) announced a significant glumetinib approval—the conditional…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights